Type 2 diabetes patients who are not overweight and who have had the disorder for less than a decade can benefit from stromal stem cells transplanted from their own bone marrow, according to a study published today in STEM CELLS Translational Medicine.
In a randomized clinical trial at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam, researchers investigated the safety and potential therapeutic value of administering bone marrow stromal stem cells to patients with Type 2 diabetes. In each case, the cells were autologous, or taken from the patients’ own bodies.